RMD Stock Recent News

RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.

The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished.

Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.